ARVO 2021: GATHER1 Study and CME After RRD Surgery
New Retina Radio by Eyetube
English - May 28, 2021 04:01 - 11 minutes - ★★★★ - 16 ratingsScience Health & Fitness Medicine Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
18-month results for GATHER1 look promising, but another pivotal study is still in the works. What else needs to happen for Zimura to become the first FDA-approved therapy for geographic atrophy? New Retina Radio spoke with Veeral Sheth, MD, about what he shared regarding the GATHER1 study at this year’s ARVO meeting.
We also spoke with Matthew Starr, MD, about his research on the development of CME following rhegmatogenous retinal detachment surgery. Could his findings help surgeons better understand the risk factors for complication after surgery?
This editorially independent podcast is supported with advertising.
18-month results for GATHER1 look promising, but another pivotal study is still in the works. What else needs to happen for Zimura to become the first FDA-approved therapy for geographic atrophy? New Retina Radio spoke with Veeral Sheth, MD, about what he shared regarding the GATHER1 study at this year’s ARVO meeting.
We also spoke with Matthew Starr, MD, about his research on the development of CME following rhegmatogenous retinal detachment surgery. Could his findings help surgeons better understand the risk factors for complication after surgery?
This editorially independent podcast is supported with advertising.